In that sense, the decision between batch, flow and CSTR operation is a central process-design exercise that should precede any major development effort.
Once this assessment has been completed and a continuous approach has been identified as the most suitable technical and economic option, the key success factors for implementation come into focus. Critical considerations then include access to suitable infrastructure, fit-for-purpose reactor design, strong engineering and scale-up expertise, and the analytical and digital tools needed to develop, control and derisk the process effectively.
Barriers to flow adoption
Teams adopting flow chemistry principles typically face a combination of technical, organisational and financial barriers. Many organisations, particularly smaller biotechs, do not have established flow platforms that can support automation, inline analytics or suitable lab- and pilotscale reactor hardware. Even when the scientific case for flow is strong, the initial effort required to install and qualify equipment can make implementation appear slower and more expensive than continuing with familiar batch methods.
A second barrier is expertise. Successful flow development requires more than synthetic chemistry knowledge alone. It depends on reaction engineering, thermal and mixing analysis, residence-time design, pressure management, process safety assessment, and, in many cases, integration of process analytical technology( PAT), photochemical, or electrochemical modules. Just as importantly, it requires experience in translating promising laboratory flow conditions into scalable, GMP-ready processes.
Flow chemistry is most effective when supported by appropriate reactor-selection logic, modelling tools, process analytics and scale-up strategies. Without these capabilities, teams may struggle to identify which steps are truly suitable for flow, how to design around heat and mass transfer constraints, or how to define a robust pathway from early development to manufacturing. This can result in hesitation, underuse of the technology or poorly targeted development effort.
Another barrier to consider is the availability of customised flow reactor modules. Standard commercial systems do not always match the needs of a given process, particularly for chemistries involving unusual residence times, corrosive media, slurry handling, photochemistry, electrochemistry or multi-phase processing.
In such cases, implementation may require a custom reactor design or rapid fabrication capability, which many biotech companies do not possess internally. The inability to access fit-for-purpose reactor hardware on demand can delay evaluation of otherwise attractive routes.
Realising the full potential of flow chemistry depends as much on early adoption, strategy and capability building as on the underlying reactions themselves. Organisations that rigorously match chemistry to the right reactor concept, invest in infrastructure and expertise and secure access to fit-for-purpose hardware are best positioned to deploy continuous processing where it genuinely adds value.
Strategic partnerships
Green chemistry principles are foundational to the development
18 SPECIALITY CHEMICALS MAGAZINE ESTABLISHED 1981